Solifenacin Succinate Tablets + Estrogen
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Overactive Bladder
Conditions
Overactive Bladder, Postmenopausal Disorder, Urination Disorders
Trial Timeline
Oct 1, 2011 → Oct 1, 2013
NCT ID
NCT01833663About Solifenacin Succinate Tablets + Estrogen
Solifenacin Succinate Tablets + Estrogen is a approved stage product being developed by Astellas Pharma for Overactive Bladder. The current trial status is completed. This product is registered under clinical trial identifier NCT01833663. Target conditions include Overactive Bladder, Postmenopausal Disorder, Urination Disorders.
What happened to similar drugs?
20 of 20 similar drugs in Overactive Bladder were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01833663 | Approved | Completed |
Competing Products
20 competing products in Overactive Bladder